In conclusion, the results of our preclinical placebo-controlled intervention study provide evidence that the therapeutic application of carvacrol dampens intestinal and extra-intestinal inflammatory responses during acute campylobacteriosis in IL-10−/− mice harboring a human gut microbiota. The gene discussed is IL10; the disease is campylobacteriosis.